Dr. Shailendra Asthana obtained his Masters degree in Bioinformatics from Allahabad University. After that, he joined Indian Agricultural research institute as a Senior Research Fellow to develop a database for the wheat genome. He then received an international MIUR fellowship from Italy as a researcher to work on viral proteins. There, he won a PhD grant to pursue his research interest with Prof. Paolo La Colla, in the Department of Biomedical Sciences University of Cagliari, ITALY. He received his PhD degree in computational Biophysics with an excellent grade. During this period he developed a lead molecule against the bovine viral diarrhea virus, and this molecule still remains one of the most potent leads available against this virus. His subsequent mechanistic studies explaining the inhibition mechanism of this molecule is widely considered as breakthrough work. Subsequently Shailendra did a three year-stint as a Postdoctoral Fellow in the Department of Physics, University of Cagliari, Italy. During this period he focused on understanding the dynamic behavior of multimeric proteins and their selectivity, the role of water molecules in molecular recognition processes, and the thermodynamic considerations guiding the stability of the protein complexes. He returned to India to join the National Institute of Pathology, Safdarjung Hospital, as a Scientist. Here, he studied the androgen receptor in breast cancer. Additionally, he used advanced bioinformatics tools to handle large sequencing data sets. However, to pursue his core interest in drug discovery research, he moved to DDRC in 2014. At DDRC Shailendra leads a structural bioinformatics team to accelerate hit identification and develop a discovery platform against multiple targets associated with metabolic disorders and other diseases. His particular interests include the intrinsic dynamics of proteins, protein-protein interaction interfaces as druggable targets, and the role of post-translational modifications (PTMs) in multi-conformational states and dynamics of proteins. His larger goal here is to incorporate such atomic level high-resolution information into the drug discovery pipeline.